Trial Profile
A randomized, open-label study of the effect of Fuzeon [enfuvirtide] plus a highly active antiretroviral therapy (HAART) compared with HAART alone on viral load suppression and safety in patients currently on antiretroviral therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Enfuvirtide (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms INTENSE
- Sponsors Roche
- 16 Apr 2008 The actual completion date for the trial is Apr 2008, actual patient number is 47.
- 16 Apr 2008 Status changed from in progress to completed according to clinicaltrials.gov.
- 26 Mar 2008 The expected completion date for this trial is now 1 Dec 2007.